Literature DB >> 26268739

Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer.

Laura S Lourdes1, Shadia I Jalal2, Nasser Hanna2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26268739      PMCID： PMC4571806          DOI： 10.1634/theoncologist.2015-0182

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  22 in total

1.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Authors:  James Chih-Hsin Yang; Yi-Long Wu; Martin Schuler; Martin Sebastian; Sanjay Popat; Nobuyuki Yamamoto; Caicun Zhou; Cheng-Ping Hu; Kenneth O'Byrne; Jifeng Feng; Shun Lu; Yunchao Huang; Sarayut L Geater; Kye Young Lee; Chun-Ming Tsai; Vera Gorbunova; Vera Hirsh; Jaafar Bennouna; Sergey Orlov; Tony Mok; Michael Boyer; Wu-Chou Su; Ki Hyeong Lee; Terufumi Kato; Dan Massey; Mehdi Shahidi; Victoria Zazulina; Lecia V Sequist
Journal:  Lancet Oncol       Date:  2015-01-12       Impact factor: 41.316

2.  Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer.

Authors:  Feiran Lou; Camelia S Sima; Valerie W Rusch; David R Jones; James Huang
Journal:  Ann Thorac Surg       Date:  2014-08-07       Impact factor: 4.330

3.  Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Authors:  Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; George Sledge; Charles E Geyer; Silvana Martino; Priya Rastogi; Julie Gralow; Sandra M Swain; Eric P Winer; Gerardo Colon-Otero; Nancy E Davidson; Eleftherios Mamounas; Jo Anne Zujewski; Norman Wolmark
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

4.  Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

Authors:  Frank Fossella; Jose R Pereira; Joachim von Pawel; Anna Pluzanska; Vera Gorbounova; Eckhard Kaukel; Karin V Mattson; Rodryg Ramlau; Aleksandra Szczesna; Panagiotis Fidias; Michael Millward; Chandra P Belani
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

5.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

Authors:  Rodrigo Arriagada; Bengt Bergman; Ariane Dunant; Thierry Le Chevalier; Jean-Pierre Pignon; Johan Vansteenkiste
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

6.  Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Authors:  Glenwood D Goss; Chris O'Callaghan; Ian Lorimer; Ming-Sound Tsao; Gregory A Masters; James Jett; Martin J Edelman; Rogerio Lilenbaum; Hak Choy; Fadlo Khuri; Katherine Pisters; David Gandara; Kemp Kernstine; Charles Butts; Jonathan Noble; Thomas A Hensing; Kendrith Rowland; Joan Schiller; Keyue Ding; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

7.  Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  John A Howington; Matthew G Blum; Andrew C Chang; Alex A Balekian; Sudish C Murthy
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

8.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Authors:  Ronald P Dematteo; Karla V Ballman; Cristina R Antonescu; Robert G Maki; Peter W T Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D McCarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar
Journal:  Lancet       Date:  2009-03-18       Impact factor: 79.321

Review 9.  How cell death shapes cancer.

Authors:  V Labi; M Erlacher
Journal:  Cell Death Dis       Date:  2015-03-05       Impact factor: 8.469

10.  Time-varying pattern of postoperative recurrence risk of early-stage (T1a-T2bN0M0) non-small cell lung cancer (NSCLC): results of a single-center study of 994 Chinese patients.

Authors:  Jian-fei Zhu; Xing-yu Feng; Xue-wen Zhang; Ying-sheng Wen; Peng Lin; Tie-hua Rong; Ling Cai; Lan-jun Zhang
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240
View more
  1 in total

Review 1.  Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?

Authors:  Lucio Buffoni; Tiziana Vavalà; Silvia Novello
Journal:  Curr Treat Options Oncol       Date:  2016-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.